
|Articles|February 27, 2014
- NSCLC (Issue 2)
- Volume 2
- Issue 1
PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.
Advertisement
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.
Read more aboutfrontline treatment considerations for lung cancer > >
Articles in this issue
almost 12 years ago
Crizotinib Resistance in ALK-Positive Lung Canceralmost 12 years ago
Clinical Update: ALK-Positive NSCLCalmost 12 years ago
Treating Older Patients With NSCLCalmost 12 years ago
Treatment of Elderly Patients With NSCLCalmost 12 years ago
Current Challenges in Molecular Testing in NSCLCalmost 12 years ago
Individualized Maintenance Therapy for NSCLCalmost 12 years ago
Frontline Treatment Considerations in Non-Small Cell Lung CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































